The week in industry: Spinal muscular atrophy treatment gets positive recommendation from NICE
This week: Vertex Pharmaceuticals and Kymera Therapeutics (both MA, USA) enter into a four-year collaboration to develop protein targeted therapies, the US FDA approves the first combination PD-L1 therapy for advanced renal cell carcinoma and Vaccitech (Berlin, Germany) is granted access to ProBioGen’s (Oxford, UK) vaccine manufacturing production platform.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>